Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PLX PHARMA INC. : Other Events (form 8-K)

03/17/2021 | 07:47am EDT
Item 8.01 Other Events



On March 16, 2021, PLx Pharma Inc. (the "Company") completed a closing of an exercise of the underwriters' option to purchase an additional 1,049,700 shares of common stock at the public offering price of $8.00 per share as part of the firm commitment underwritten offering that initially closed on March 5, 2021, resulting in additional net proceeds to the Company of approximately $7.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. After giving effect to this exercise of the over-allotment option, the total number of shares sold by Company in the public offering increased to 8,924,700 shares and net proceeds increased to approximately $66.9 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.

Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. acted as the joint book-running managers for the public offering. The shares were offered by the Company pursuant to an automatically effective shelf registration statement on Form S-3 (No. 333-230478) previously filed with the U.S. Securities and Exchange Commission (the "SEC") and declared effective by the SEC on April 4, 2019. A prospectus supplement relating to, and describing the terms of, the offering was previously filed with the SEC on March 4, 2021 and is available on the SEC's website at http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering can also be obtained from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863 or by e-mail at prospectus@raymondjames.com; or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY, 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com.

© Edgar Online, source Glimpses

All news about PLX PHARMA INC.
08/02PLx Pharma Inc.'s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month
GL
07/27PLX PHARMA : to Make Vazalore Available in Over 2,400 Rite Aid Stores in August
MT
07/26PLX PHARMA : VAZALORE to Launch in Over 2,400 Rite Aid Stores in August
AQ
07/26PLx Pharma Inc.’s VAZALORE to Launch in Over 2,400 Rite Aid Stores in August
CI
07/22PLX PHARMA : to Discuss 2021 Second Quarter Financial Results on August 6, 2021 ..
AQ
07/20AFTER HOURS WATCH LIST SCORECARD : Plxp, ppg, ardx
MT
07/20PLx Shares Rise as Walgreens Set to Carry Vazalore in Stores
DJ
07/20SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Tuesday
MT
07/20PLX PHARMA : JMP Securities Adjusts PLx Pharma's Price Target to $21 From $12, K..
MT
07/19MT NEWSWIRES AFTER HOURS WATCH LIST : Plxp, ppg, ardx
MT
More news
Financials (USD)
Sales 2021 5,73 M - -
Net income 2021 -27,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -13,7x
Yield 2021 -
Capitalization 416 M 416 M -
Capi. / Sales 2021 72,5x
Capi. / Sales 2022 15,7x
Nbr of Employees 10
Free-Float 81,8%
Chart PLX PHARMA INC.
Duration : Period :
PLx Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLX PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 18,08 $
Average target price 21,50 $
Spread / Average Target 18,9%
EPS Revisions
Managers and Directors
Natasha Giordano President, Chief Executive Officer & Director
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain
Michael J. Valentino Executive Chairman
Gary S. Balkema Independent Director
Kirk K. Calhoun Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PLX PHARMA INC.227.54%416
GILEAD SCIENCES, INC.17.22%85 648
BIONTECH SE317.33%79 303
WUXI APPTEC CO., LTD.36.10%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-16.09%52 296